Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CASP1 | P29466 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17796721 | 0.78 | ALDH1A1 (0.34) | ALDH1A1LMNAKDM4EMAPTMEN1 | |
| SCHEMBL17796722 | 0.78 | ALDH1A1 (0.34) | ALDH1A1LMNAKDM4EMAPTMEN1 | |
| SCHEMBL6125259 | 0.77 | BAZ2B (0.37) | ALDH1A1LMNAKDM4EL3MBTL1MAPT | |
| SCHEMBL894594 | 0.72 | — | — | |
| SCHEMBL1064764 | 0.72 | KDM4E (0.33) | ALDH1A1KDM4EL3MBTL1NR4A1 | |
| SCHEMBL10537 | 0.72 | KDM4E (0.38) | ALDH1A1KDM4EL3MBTL1NR4A1 | |
| SCHEMBL16446616 | 0.72 | KDM4E (0.33) | ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL17796551 | 0.71 | KDM4E (0.31) | ALDH1A1LMNAKDM4EL3MBTL1MAPT | |
| SCHEMBL14108169 | 0.71 | — | — | |
| SCHEMBL16866129 | 0.70 | NR4A1 (0.36) | ALDH1A1LMNAKDM4EL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3029031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | ALDH1A1 4734/4885LMNA 2866/4885TRIM24 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.